• Aptamer-based COVID-19 diagnostics

Aptamer Group advances COVID-19 testing capabilities with Integumen

Aptamer Group Ltd, the developer of diagnostic and therapeutic aptamer reagents, is pleased to announce further progress in their collaboration with Integumen plc (AIM: SKIN) to develop Microtox PD, a wastewater detection system for COVID-19. Aptamer Group is also collaborating with Integumen on the development of a new personalised rapid COVID-19 breath test, Microtx BT, […]

Rapid small molecules detection using our aptamer-based displacement approach

The challenge
Small molecules such as antibiotics, drugs, toxins and food additives are often perceived as difficult targets to obtain a suitable affinity ligand. The development of rapid, cost-effective, single-step assays for the sensitive and specific detection of small molecules are very attractive for many applications ranging from life sciences to environmental analysis. Unfortunately, current […]

Aptamer based delivery of CRISPR/Cas9 for cancer gene therapy without the need for electroporation

CRISPR/Cas9 therapeutics have been in vitro techniques historically. This review shows the promise of potential in vivo aptamer based delivery of CRISPR/Cas9 therapeutics.

Precise editing of DNA sequences in the human genome can correct mutations or introduce novel genetic functionality, thus providing promising solutions to various diseases. Amongst the various diverse gene editing technology to […]

Aptamers and their applications in RNAi technology

The RNA interference (RNAi) era, started by Fire and Mello in 1998 completely changed the vision of research involving cell control and therapeutic intervention. RNAi machinery starts from a long dsRNA and pre-microRNA (pre-miRNA) that is cleaved by the ‘Dicer’ enzyme in a short dsRNA fragments called small interfering RNA (siRNA) and miRNA, respectively. This, […]

Aptamers and their applications in immunohistochemistry

Immunohistochemistry has helped to make surgical pathology the ‘gold standard’ for tumour diagnosis. Antibodies have been used extensively as the molecular probes; however, there have been issues with their specificity, which is the most critical determining factor in IHC.

Previous reports have suggested that 40-50 % of diagnostic inconsistencies are related to poor antibody selection, cross […]

Integumen signs MTA with Aptamer Group Ltd

Collaboration to use aptamers in a device to detect SARS-CoV-2 in wastewater
Aptamer Group, developers of Aptamer reagents, is pleased to announce that it has signed a Material Transfer Agreement (“MTA”) with the Integumen. This recently established collaboration is to use  Aptamers in a device to detect SARS-CoV-2 in wastewater. Once ready, the Aptamers will play […]

Aptamer Group and Cytiva form new collaboration for the development of COVID-19 Rapid Test

Collaboration to produce a rapid test for the COVID-19 coronavirus infection
Aptamer Group, is pleased to announce that it has entered into a collaboration with Cytiva, formerly known as GE Healthcare Life Sciences. The company will use its recently developed aptamer reagent combined with Cytiva’s lateral flow technology to produce a Lateral Flow Device (LFD)*. Aptamer […]

Aptamer based strategies for effectively crossing the Blood Brain Barrier

The blood brain barrier (BBB) is a highly specialized network of blood vessels that effectively separates the brain environment from the circulatory system. Delivering drugs into the brain environment has historically been a challenge. This is due to the nature of the BBB anatomy, as it is composed of polarized endothelial cells that are connected […]

Aptamer mediated targeted delivery of cancer therapeutics

The major challenges of cancer research include finding ways to maximize the tolerated dose of chemotherapeutic drug given and balancing this with an acceptable toxicity profile. One promising approach is to transport drugs to their specific target destinations by increasing the selectivity to cancerous cells. This in turn, can shield the drugs from elimination and […]

Aptamer Group making headlines on their Point of Care COVID19 reagent developments

Arron Tolley, CEO of Aptamer Group discusses the teams progress on COVID19 tests: